JP2020504722A - 血管密度を増加させる方法 - Google Patents

血管密度を増加させる方法 Download PDF

Info

Publication number
JP2020504722A
JP2020504722A JP2019533084A JP2019533084A JP2020504722A JP 2020504722 A JP2020504722 A JP 2020504722A JP 2019533084 A JP2019533084 A JP 2019533084A JP 2019533084 A JP2019533084 A JP 2019533084A JP 2020504722 A JP2020504722 A JP 2020504722A
Authority
JP
Japan
Prior art keywords
subject
nad
sirt1
administering
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019533084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504722A5 (cg-RX-API-DMAC7.html
Inventor
エドワード ウー、リンゼイ
エドワード ウー、リンゼイ
アンドリュー シンクレア、デイビッド
アンドリュー シンクレア、デイビッド
ダス、アビーラップ
Original Assignee
ニューサウス イノベーションズ ピーティーワイ リミテッド
ニューサウス イノベーションズ ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016905310A external-priority patent/AU2016905310A0/en
Application filed by ニューサウス イノベーションズ ピーティーワイ リミテッド, ニューサウス イノベーションズ ピーティーワイ リミテッド filed Critical ニューサウス イノベーションズ ピーティーワイ リミテッド
Publication of JP2020504722A publication Critical patent/JP2020504722A/ja
Publication of JP2020504722A5 publication Critical patent/JP2020504722A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019533084A 2016-12-21 2017-12-21 血管密度を増加させる方法 Pending JP2020504722A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016905310A AU2016905310A0 (en) 2016-12-21 Methods for enhancing vascular density
AU2016905310 2016-12-21
PCT/AU2017/051435 WO2018112541A1 (en) 2016-12-21 2017-12-21 Methods for enhancing vascular density

Publications (2)

Publication Number Publication Date
JP2020504722A true JP2020504722A (ja) 2020-02-13
JP2020504722A5 JP2020504722A5 (cg-RX-API-DMAC7.html) 2021-02-04

Family

ID=62624132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019533084A Pending JP2020504722A (ja) 2016-12-21 2017-12-21 血管密度を増加させる方法

Country Status (8)

Country Link
US (2) US20190328761A1 (cg-RX-API-DMAC7.html)
EP (1) EP3558312A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020504722A (cg-RX-API-DMAC7.html)
KR (1) KR20190110547A (cg-RX-API-DMAC7.html)
CN (2) CN116509885A (cg-RX-API-DMAC7.html)
AU (1) AU2017383100B2 (cg-RX-API-DMAC7.html)
CA (1) CA3047437A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018112541A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7555159B1 (ja) * 2023-06-29 2024-09-24 株式会社レースホース 動物用栄養組成物
WO2024237195A1 (ja) 2023-05-12 2024-11-21 明治ホールディングス株式会社 子どもの発達促進のための組成物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3331894B1 (en) 2015-08-05 2021-02-17 Metro International Biotech, LLC Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN109674808A (zh) * 2019-01-30 2019-04-26 四川大学 β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途
CN110638826A (zh) * 2019-10-09 2020-01-03 泓博元生命科技（深圳）有限公司 Nadh和/或nmn在制备肌肉增强或抑制肌肉量下降的药物或保健品中的应用
CN110734950A (zh) * 2019-11-14 2020-01-31 南方医科大学珠江医院 一种nmn治疗与改善cmva的相关性的体外实验法
CN110974781A (zh) * 2020-01-02 2020-04-10 崔立峰 一种用于皮肤创面修复的凝胶
IL296262A (en) * 2020-03-11 2022-11-01 Massachusetts Eye & Ear Infirmary Gene therapy for nmnat1-related retinal degeneration
EP4070799A1 (en) * 2021-04-08 2022-10-12 Nuvamid SA Compositions for the improvement of sport performance
WO2023159601A1 (en) * 2022-02-28 2023-08-31 Shenzhen University Use of agent deacetylating klf4 to promote transcriptional activity thereof, method for maintaining functions of pulmonary artery endothelial cells, and method for treating pulmonary arterial hypertension
CN115227712A (zh) * 2022-07-26 2022-10-25 上海市第五人民医院 NaHS在制备治疗骨质疏松药物中的应用
CN117771375A (zh) * 2024-01-31 2024-03-29 中山大学附属第三医院 SIRT1/PGC-1α通路激活剂的新用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
WO2016086088A2 (en) * 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1853590A1 (en) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
US7855289B2 (en) * 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CN102985553B (zh) * 2010-04-15 2015-11-25 西特里斯药业公司 沉默调节蛋白活化剂和活化测定
US20140065099A1 (en) * 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
WO2013002879A1 (en) * 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
US9877981B2 (en) * 2012-10-09 2018-01-30 President And Fellows Of Harvard College NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
US20170087180A1 (en) * 2014-06-03 2017-03-30 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501343A (ja) * 2004-06-04 2008-01-24 ワシントン・ユニバーシティ 神経障害を治療するための方法および組成物
WO2016086088A2 (en) * 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGEING RESEARCH REVIEWS, vol. 21, JPN6021043126, 2015, pages 1 - 15, ISSN: 0005027149 *
FOOD AND CHEMICAL TOXICOLOGY, vol. 61, JPN6022027463, 2013, pages 53 - 59, ISSN: 0004817866 *
HYPERTENSION, vol. Vol.68, Issue suppl_1, JPN6021043121, 13 December 2016 (2016-12-13), pages 141, ISSN: 0005027151 *
MOLECULAR AND CELLULAR BIOLOGY, vol. 33, no. 6, JPN6021043123, 2013, pages 1104 - 1113, ISSN: 0005027150 *
ビタミン, vol. 90, JPN6021043124, June 2016 (2016-06-01), pages 286 - 289, ISSN: 0004817867 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024237195A1 (ja) 2023-05-12 2024-11-21 明治ホールディングス株式会社 子どもの発達促進のための組成物
JP7555159B1 (ja) * 2023-06-29 2024-09-24 株式会社レースホース 動物用栄養組成物
WO2025004279A1 (ja) * 2023-06-29 2025-01-02 株式会社レースホース 動物用栄養組成物
JP2025010131A (ja) * 2023-06-29 2025-01-20 株式会社レースホース 動物用栄養組成物
JP7674710B2 (ja) 2023-06-29 2025-05-12 株式会社希星 動物用栄養組成物

Also Published As

Publication number Publication date
EP3558312A4 (en) 2021-01-13
KR20190110547A (ko) 2019-09-30
CN116509885A (zh) 2023-08-01
US20190328761A1 (en) 2019-10-31
CN110325190A (zh) 2019-10-11
AU2017383100A1 (en) 2019-07-18
EP3558312A1 (en) 2019-10-30
WO2018112541A1 (en) 2018-06-28
US20230149437A1 (en) 2023-05-18
CA3047437A1 (en) 2018-06-28
AU2017383100B2 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
US20230149437A1 (en) Methods for enhancing vascular density
Das et al. Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging
Rong et al. Hypoxic pretreatment of small extracellular vesicles mediates cartilage repair in osteoarthritis by delivering miR-216a-5p
Liu et al. Hypoxia pretreatment of bone marrow mesenchymal stem cells facilitates angiogenesis by improving the function of endothelial cells in diabetic rats with lower ischemia
Huang et al. Downregulation of microRNA‐155 stimulates sevoflurane‐mediated cardioprotection against myocardial ischemia/reperfusion injury by binding to SIRT1 in mice
Yang et al. Extracellular vesicles-encapsulated microRNA-29b-3p from bone marrow‐derived mesenchymal stem cells promotes fracture healing via modulation of the PTEN/PI3K/AKT axis
CN106062194A (zh) 用于调整肌腱愈合的材料和方法
S. Xu et al. Epigenetics in vascular disease–therapeutic potential of new agents
JP6978774B2 (ja) 心不全の予防又は治療のための医薬組成物
Zhou et al. Contrasting roles of E2F2 and E2F3 in endothelial cell growth and ischemic angiogenesis
Swoboda et al. Perspectives on clinical trials in spinal muscular atrophy
Lee et al. Differential effects of NADPH oxidase and xanthine oxidase inhibition on sympathetic reinnervation in postinfarct rat hearts
US10918655B2 (en) Stimulating platelet generation by activating mitochondrial biogenesis
US20170049822A1 (en) Methods of enhancing stem cell engraftment
US20170014455A1 (en) Inducing brown fat fate and function
Liu et al. Cardiomyocyte S1PR1 promotes cardiac regeneration via AKT/mTORC1 signaling pathway
Grødem et al. Deciphering the role of aggrecan in parvalbumin interneurons: unexpected outcomes from a conditional ACAN knockout that eliminates WFA+ perineuronal nets
CN115851902B (zh) Rp11-544d21.2的制药用途、在制备抗心衰药物方面的用途及药物与制备方法
US20250163141A1 (en) Ccl4 antagonist for inhibiting vascular aging
Chen et al. The mechanism of IL-1β-mediated Piezo1 regulating chondrocyte autophagy and apoptosis through PI3K/AKT/mTOR signaling pathway
Mee-inta et al. Enhancement of meningeal lymphatic structure and function through running exercise mitigates amyloidosis in an Alzheimer’s disease mouse model
Johnson et al. AAV9 gene therapy restores lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease
Wu Ankyrin-B And Mtor Complex 1 In The Regulation Of Electrical Activities In The Heart
Jose The ROLE OF LIPID PHOSPHATE PHOSPHATASE 3 IN CARDIAC ENERGY METABOLISM.
Pfeiffer Optogenetic neuromodulation in a rodent model of depression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190910

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20200925

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20201009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230404